Angle PLC Sidney Kimmel Cancer Centre (6429K)
April 20 2015 - 2:00AM
UK Regulatory
TIDMAGL
RNS Number : 6429K
Angle PLC
20 April 2015
For immediate release 20 April 2015
ANGLE plc ("the Company")
RESULTS FROM THE SIDNEY KIMMEL CANCER CENTER AT THOMAS JEFFERSON
UNIVERSITY
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is pleased to announce that the Sidney Kimmel Cancer Center at
Thomas Jefferson University, Philadelphia, one of its key opinion
leaders, has published results of its work evaluating the potential
for ANGLE's Parsortix system to be used in single cell analysis for
breast cancer.
The results are being published as a poster at the American
Association for Cancer Research Annual Meeting 2015 being held in
Philadelphia ("AACR"). AACR is one of the world's largest and most
influential cancer conferences. The poster can be downloaded from
the ANGLE website here
http://www.angleplc.com/the-parsortix-system/download-files/.
A key challenge in investigating the metastatic process and
improving the therapeutic benefit of cancer treatment is the
heterogeneity (genetic variability) of the cancer cells. There are
major potential benefits if circulating tumour cells (CTCs) can be
harvested from patient blood and then processed individually
one-by-one as intact cells for analysis. Technically this requires
a high performance CTC capture and harvesting system that provides
harvested CTCs in a form capable of then being processed by a
single cell analysis system.
The Sidney Kimmel Cancer Center at Thomas Jefferson University
have successfully tested the Parsortix system in combination with
the single cell analysis DEPArray system to isolate single cancer
cells from blood samples spiked with cultured breast cancer cells.
The team proved the ability to manipulate the individual cancer
cells from the Parsortix system and to correctly identify two
breast cancer related genes (Estrogen receptor alpha (ESR1) and
p53) on the cells using standard PCR analysis techniques.
The research collaboration was led by Dr Massimo Cristofanilli,
an internationally renowned breast cancer researcher and clinician,
and Director of the Jefferson Breast Care Center at the Sidney
Kimmel Cancer Center and Thomas Jefferson University and Hospitals.
Dr Cristofanilli has been an acknowledged leader in the CTC field
since 2004, when his study on CTCs was published in The New England
Journal of Medicine.
The work will now focus on molecular analysis in specified
disease status and treatment settings to better identify clinical
applications for more effective treatment of women with metastatic
breast cancer.
Dr Massimo Cristofanilli, Director of the Jefferson Breast Care
Center at the Sidney Kimmel Cancer Center and Thomas Jefferson
University and Hospitals, commented:
"We demonstrated that using the Parsortix system in conjunction
with DEPArray we are able to isolate single, uncontaminated tumor
cells to achieve single cell molecular analysis. The use of single
cells is emerging as a powerful approach to molecular analysis in
oncology. The Parsortix system has the ability to advance molecular
testing, study cancer heterogeneity and apply concepts of precision
medicine to breast cancer patients' care."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The ability to capture and harvest individual CTCs for routine
analysis is an important step that has proved extremely difficult
until now. Our aim is that the Parsortix system will provide a
simple and effective way to harvest CTCs for mutation, gene
expression and other types of molecular analysis so that there is a
way to determine which drugs may benefit individual patients."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles, Jane Glover 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
two granted US patents and three extensive families of patents
being progressed worldwide. The system is based on a microfluidic
device that captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The increase in cancer to a 1 in 3 lifetime incidence is set to
drive a multi $billion clinical market. The Parsortix system is
designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESDGGDSCDBBGUC
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024